Testing when flu vaccine is given in people with chronic kidney failure
Tests timing of flu vaccine and immune response in adults with chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure
Key facts
- Where
- Nice, FranceSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT06907667, who can take part
Where in France
- CHU Nice - Hôpital Pasteur 2Nice, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Nice
- Trial code
- NCT06907667
- Record updated
- 15 May 2026
- Original description
Immune response to influenza vaccine in patients with chronic renal insufficiency.Read full original descriptionShow less
Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure - CHRONOVAX 2
Immune response to influenza vaccine in patients with chronic renal insufficiency.
Inclusion: Chronic renal failure patient at stage 4 or 5 (i.e. estimated GFR < 30mL/min/1.73m2); or Dialysis patient; or renal transplant patient regardless of GFR; Age ≥ 18 years; Indication for influenza vaccination; Express free and informed consent.
Exclusion: Previous influenza vaccination for the current season; Treatments with a major impact on vaccine response:; Treatment of rejection within the previous 3 months; Renal transplantation with induction performed within the previous 6 months; Immunosuppressive treatment including CTLA4 agonist, complement inhibitor, anti-CD20; Known hypersensitivity to influenza vaccine or egg proteins; Current infection; Current acute illness; Treatments that may distort the serological response: Polyvalent immunoglobulin infusion within the preceding 3 months; Vulnerable persons (minors, adults under guardianship or trusteeship, persons deprived of their liberty, persons unable to speak French); Subjects not affiliated to Social Security.